ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, P.
Right arrow Articles by Guo, Q.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, P.
Right arrow Articles by Guo, Q.
Annals of Clinical & Laboratory Science 35:278-284 (2005)
© 2005 Association of Clinical Scientists

Decoy Androgen-Responsive Element DNA Can Inhibit Androgen Receptor Transactivation of the PSA Promoter Gene

Pengju Zhang1, Jianye Zhang1, Charles Y. F. Young2, Pai C. Kao3, Weiwen Chen1, Anli Jiang1, Lianying Zhang1 and Qiang Guo1
1 Institute of Biochemistry and Molecular Biology, School of Medicine, Shandong University, Jinan, China; 2 Section of Urology Research and 3 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA

Address correspondence to Dr. Jianye Zhang, Institute of Biochemistry and Molecular Biology, Shandong University, Jinan 250012, People’s Republic of China; tel 86 531 838 2092; e-mail zhjy{at}sdu.edu.cn.

Chemotherapy, hormonal therapy, or surgery may cause devastating toxic or other side effects. Androgen receptors (ARs) in the cytoplasm are activated by binding with androgen. Androgen-activated ARs bind to a specific genomic DNA sequence, the androgen-responsive element (ARE), and initiate gene expression at the transcriptional level. Even without androgen activation, ARs may have a role in androgen-refractory prostate cancer. Thus, inhibition of AR activity may have therapeutic value. We applied a genetic reporter of the Dual-Luciferase Assay System to test whether a short double-stranded genomic DNA containing prostate-specific antigen (PSA) ARE sequence as decoy DNA would inhibit the function of activated AR. A 21-mer phosphorothioated PSA ARE decoy DNA was synthesized, with a plasmid vector containing the PSA promoter upstream from a luciferase gene, the reporter gene. The promoter and reporter were co-transfected into a human prostate cancer cell line PC3-M with the aid of Lipofectamin 2000. After 24 hr exposure to androgens, the cells were lysed and luciferase activity measured to determine the ARE decoy inhibitory effect on the function of ARs. Luciferase activity was reduced significantly in the ARE decoy transfected cells but not with inactive control decoy. The results demonstrate that ARE decoy DNA can effectively suppress androgen-activated ARs in prostate cancer cells and indicate the potential utility of decoy DNA for developing a novel therapy for prostate cancer.

Keywords: androgen receptor, androgen-responsive element, prostate cancer, reporter gene






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the Association of Clinical Scientists.